Chronic myeloid leukemia (CML) is a stem cell disorder characterized by unrestricted proliferation of the yeloid series that occurs due to the BCR-ABL fusion oncogene as a result of reciprocal translocation t(9;22) q34;q11). This discovery has made this particular domain a target for future efforts to cure CML. Imatinib evolutionized the treatment options for CML and gave encouraging results both in case of safety as well as lerability profile as compared to agents such as hydroxyurea or busulfan given before Imatinib. However, about 2-4% of patients show resistance and mutations have been found to be one of the reasons for its development. European Leukemianet gives recommendations for BCR-ABL mutational analysis along with other tyrosine kinase inhibitors (TKIs) that should be administered according to the mutations harbored in a patient. The following overview gives recommendations for monitoring patients on the basis of their mutational status.